A phase III, double-blind, randomized, active-controlled, two-armed, multicenter, efficacy and safety assessment (ACTAMESA) of org 5222 and olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder.

Trial Profile

A phase III, double-blind, randomized, active-controlled, two-armed, multicenter, efficacy and safety assessment (ACTAMESA) of org 5222 and olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTAMESA
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Mar 2010 Results published in Pharmacopsychiatry.
    • 06 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.
    • 06 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top